Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

VinFuture announces the 2023 Sci-Tech week and award ceremony

Vingroup

HANOI, VIETNAM - Media OutReach - 28 November 2023 - VinFuture Foundation officially announces the agenda for the third Science and Technology Week slated to take place from December 18th to 21st, 2023, in Hanoi, Vietnam. This series of world-class events will bring together leading scientists and experts in pivotal technological domains, including semiconductor technology, precision medicine, green transportation infrastructure, and artificial intelligence. The pinnacle of the Sci-Tech week will be the VinFuture Prize Award Ceremony, recognizing scientists for their groundbreaking achievements that significantly impact the lives of millions worldwide. The 2023 VinFuture Sci-Tech Week and the VinFuture Prize Award Ceremony are among the most highly anticipated annual events in the global science and technology community. This year, centered around the theme of “Boundless Unity,” the four-day 2023 VinFuture Sci-Tech Week comprised a wide array of engagements, including the “ Science for Life ” Symposia, the “ VinFuture Discovery Talk Series,” the prestigious “ VinFuture Prize Award Ceremony,” and “ Talk Future: Dialogue with the 2023 VinFuture Prize Laureates.” Commencing the series of events is the “Science for Life” Symposia taking place on December 18th-19th, including four sessions with the topics: “Semiconductors Unleashed: The Backbone of Modern Innovation,” “Advancing Precision Immunology Therapy for the Treatment of Autoimmune Disorders,” “Sustainable Infrastructure and Green Transportation,” and “Artificial Intelligence: Transformative Opportunities and Challenges.” The symposia serve as an eminent platform that unites policymakers, scientists, experts, and businessmen from prestigious domestic and international organizations. Guests attending the symposia will meet and discuss with distinguished scientists such as Professor Teck-Seng Low, Senior Vice President at the National University of Singapore (Singapore); Dr. Sadasivan (Sadas) Shankar, Research Technology Manager at SLAC National Laboratory in Stanford University (USA); Professor Shimon Sakaguchi, Immunologist and Distinguished Professor at the Immunology Frontier Research Center (IFReC), Osaka University (Japan); Professor Jang-Soo Chun, Gwangju Institute of Science, and Technology and Director of the Korea National Creative Research Initiatives Center for Osteoarthritis Pathogenesis (South Korea); Professor Christian Borgs, Director of the Bakar Institute of Digital Materials for the Planet (BIDMaP) and Member of the Berkeley Artificial Intelligence Research (BAIR) Lab at University of California, Berkeley (USA) … The highlight of VinFuture Season 3 is the connection activities under the “ VinFuture Discovery Talk Series ” - organized for the first time to cultivate partnerships and delve into potential technology transfers at renowned research institutes and universities in Vietnam. Nine participating organizations in Hanoi will engage in profound discussions with globally acclaimed scientists. These conversations will revolve around pivotal topics, including “ Ending AIDS: Developing new prevention technologies for young women, ” “ Building research capacity to address global health issues in low- and middle-income countries, ” “ COVID-19: Advancing an evidence-based response, ” “ Agriculture's path to net zero emissions: The role of livestock, ” etc. The pinnacle of this series culminates in the highly anticipated 2023 VinFuture Prize Award Ceremony, poised to take place on the evening of December 20th, 2023, at the Ho Guom Opera House. This ceremony, under the resounding theme of “Boundless Unity,” serves as the grand stage for unveiling the Laureates of the VinFuture Prize Season 3, whose technological breakthroughs were meticulously curated from a comprehensive pool of nearly 1,400 nominations spanning over 90 countries and territories worldwide. Wrapping up the VinFutureSci-Tech Week is the grand finale: “ Talk Future: Dialogue with the 2023 VinFuture Prize Laureates, ” scheduled for December 21st, 2023. Attendees can seize the morning session to personally connect with the esteemed 2023 VinFuture Prize Laureates as they share the inspirational scientific research journey that led them to prestigious accolades. Later in the afternoon, the Laureates will deliver an enthralling presentation catered towards exceptional young scientists, gifted students, innovative businesses, and the startup community, all eager to implement groundbreaking scientific advancements into practical applications. The VinFuture Prize has entered its third year with the prestige and stature increasingly affirmed by the global science and technology community, recognized on par with the world’s top prestigious awards. In Vietnam, the VinFuture Foundation and the VinFuture Prize also have a unique meaning, not only serve as a bridge to connect the world’s outstanding minds with the Vietnamese science and technology community but also contribute to inspiring and motivating Vietnamese science to catch up quickly and advance further on the global science and technology map. EVENT SCHEDULE FOR THE 2023 VINFUTURE SCI-TECH WEEK 1. “Science for Life” Symposia Date and time: 9:00 am - 3:45 pm, December 18th-19th, 2023 Location: Almaz International Convention Center, Hoa Lan Street, Vinhomes Riverside, Long Bien, Hanoi 2. VinFuture Discovery Talk Series Date and time: December 18th-21st, 2023 Anticipated locations: Nine (09) participating institutes, universities, and organizations 3. 2023 VinFuture Prize Award Ceremony Date and time: 8:00 pm – 10:00 pm, December 20th, 2023 Location: Ho Guom Opera House, 40 Hang Bai, Hoan Kiem, Hanoi 4. Talk Future: Dialogue with the 2023 VinFuture Prize Laureates Date and time: 9:00 am – 4:00 pm, December 21st, 2023 Location: VinUniversity, Vinhomes Ocean Park, Gia Lam, Hanoi About the VinFuture Prize The VinFuture Foundation, established on International Human Solidarity Day on December 20th, 2020, is a non-profit organization co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The Foundation's core activity is awarding the annual VinFuture Prize, which recognizes transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide. The VinFuture Prize consists of four prestigious awards presented each year. The most esteemed is the VinFuture Grand Prize, valued at US$3 million, making it one of the largest annual prizes globally. Additionally, there are three Special Prizes, each valued at US$500,000, specifically dedicated to honoring female innovators, innovators from developing countries, and innovators with outstanding achievements in emerging fields. In pursuit of its mission, the Foundation undertakes various activities. These include engaging in strategic grantmaking initiatives, fostering intellectual connections, and collaborating in the advancement of science and technology. Learn more at: https://vinfutureprize.org. Contact Details Media Contact v.chidqd1@vingroup.net

November 28, 2023 09:57 AM Eastern Standard Time

Image

Syra Health Corp announces company has launched a new digital health product SyraBot

Syra Health Corp.

Syra Health Corp Executive Chairman and President Sandeep Allam joined Steve Darling from Proactive to share the introduction of SyraBot. This innovation is a new offering from the company's Digital Health business unit. SyraBot represents a significant leap in Syra Health's commitment to enhancing user engagement through technology. It is an AI-backed chatbot designed to be human-centric, providing immediate and conversational style responses to users' inquiries on healthcare organizations' websites. The chatbot is engineered to ensure that information is readily accessible around the clock, every day of the week. SyraBot stands out due to its inclusivity, supporting over 200 languages and dialects, and its accessibility, ensuring that the information is understandable even at a fifth-grade reading level. Furthermore, Syra Health has tailored SyraBot to cater to three distinct sectors in the healthcare industry: payers, providers, and state governments, demonstrating the company's strategic approach to meeting diverse needs within the healthcare ecosystem. In addition to the launch of SyraBot, Allam discussed Syra Health's financial milestones, highlighting the company's performance in the third quarter of 2023. The company observed a revenue of $1.58 million, marking a 4% increase from the $1.51 million reported in the third quarter of the previous year. Notably, the Population Health and Health Education segments, driven by epidemiology and reporting services, experienced a substantial revenue surge, with a reported 400% growth. This financial uptick underscores the company's progress and the burgeoning demand for its specialized services in the healthcare domain. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

November 28, 2023 09:05 AM Eastern Standard Time

Video

Introducing Doceree Insights: Revolutionizing Healthcare Marketing Analytics with the Power of AI

Doceree Inc

Today, Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, proudly unveils its new groundbreaking offering – Insights. Inspired by tools like ChatGPT, this innovative solution transforms the way healthcare marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights empowers healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from your marketing campaigns. Healthcare marketers often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. At the heart of Insights is the ability for marketers to pose those questions directly to the platform, and in return, Insights provides data-driven answers in the form of interactive, exportable data visualizations. In an industry marked by evolving trends and ever-increasing demands, healthcare marketers face the challenge of understanding their campaign performance and making data-driven decisions. To address this need, Doceree has developed Insights, a ChatGPT-style tool designed to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, marketers can explore all their campaign data – including physician and provider level data (PLD). By leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights can answer detailed questions about campaign performance at the individual level. Data and analytics that were previously fragmented and complex, are now easily accessible on-demand with this innovative tool. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand the marketer’s question and get them the answer they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. This interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it even easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/us/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree is a global platform building unique solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs at scale. To learn more, visit doceree.com. Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/

November 28, 2023 08:30 AM Eastern Standard Time

Image

Doceree introduces AI-powered Insights to revolutionize Analytics in Pharma Marketing

Doceree Inc

Doceree, the leading global platform building unprecedented solutions for healthcare professional (HCP) messaging, today unveiled its groundbreaking new offering – Insights. Inspired by tools like ChatGPT, this innovative solution is set to transform the way pharma marketers access and interpret data. As the latest addition to the suite of AI-powered tools on the platform, Insights will empower healthcare marketers with a game-changing approach to analytics, making it easier than ever to unravel crucial business insights from marketing campaigns. In an industry marked by evolving trends and ever-increasing demands, pharma marketers face the challenge of understanding their campaign performance and making data-driven decisions. They often know the business questions they need answered, but don’t always know what data and analytics will help them find those answers. To address this need, Doceree developed Insights to simplify the analytics process with on-demand access to vital information quickly and effortlessly. With Insights, pharma marketers can explore all their campaign data by simply posing campaign related questions directly to the platform and receive data-driven answers in the form of interactive, exportable data visualizations. Leveraging Doceree’s proprietary HCP identity-resolution technology Espyian TM, Insights is designed to make data and analytics easily accessible and on-demand, that was previously fragmented and complex. Using artificial intelligence, Insights harnesses the power of natural language processing (NLP) to interpret and understand pharma marketers’ questions and get them the answers they seek. Insights eliminates the need to sift through static charts and predefined dashboards that often hinder quick and efficient data exploration. The interactive, AI-powered tool also allows users to export and incorporate the right data and visualizations into their own branded presentations, making it easier for marketers to tell their story with data. “ Doceree is committed to finding the bottlenecks in pharma messaging and bridging them with its AI-powered, category-focused platform and end-to-end solutions that allow pharma marketers to activate top-performing campaigns, while also effectively tracking their KPIs. With our new offering- Insights, we are set to revolutionize healthcare marketing analytics, making data-driven decisions for pharma marketers, as easy as asking a question,” said Harshit Jain MD, Founder & Global CEO at Doceree. In the competitive landscape of healthcare marketing analytics, Insights stands out as a powerful tool that simplifies the process of understanding campaign performance. By allowing customers to pose questions directly to the platform, they can quickly identify and access the precise data they require, without the need for advanced analytics skills. Key Benefits of Doceree Insights: Intuitive & AI-Powered | Helps find actionable insights and answers to questions quickly, easily, without the need for advanced analytical skills Exportable | Enables pharma marketers to tell their story their way, by allowing incorporation of the right data and visualizations into branded presentations and other materials with the ‘Export’ function On-Demand | Eliminates the frustration and inflexibility of static charts and predefined dashboards; marketers can simply ask questions and Insights will return the precise data in the form of interactive visualizations. Doceree Insights is available for healthcare marketers across the globe. For more information about Insights and how it can transform healthcare marketing analytics, please visit https://doceree.com/uk/doceree-insights/ or contact partner@doceree.com. About Doceree Doceree, the world's first global network of physician-only platforms, offers a cutting-edge solution to programmatically reach HCPs where they consume information in their professional mindset, including medical journals, education platforms, and physician networks. Their proprietary physician identity resolution technology, ESPYIANTM, allows brands to showcase the right information to the right physician at the most opportune moments based on their specialty, location, and professional interests. To learn more, visit https://doceree.com/uk/ Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/uk/

November 28, 2023 08:00 AM Eastern Standard Time

Image

Creo Medical Group reveals good growth prospects at Capital Markets Day - Proactive Research Analyst

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO), an innovative UK-based medical technology company, recently showcased significant advancements during their Capital Markets Day, as highlighted by Proactive Research Analyst John Savin in his latest research note. The primary focus was on Creo's new version of their Speedboat product, Speedboat UltraSlim, now compatible with all endoscopy systems worldwide, which marks a major leap in bowel surgery technology for removing cancerous and precancerous polyps. This miniaturization, integrating multiple surgical functions into a 2.8 mm diameter device, signifies Creo's technological prowess and opens a broader market reach. Another critical development is Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company. Creo's technology, particularly in coagulation, is seen as pivotal for these partnerships. The company is expected to earn royalties from its technological contributions, enhancing its revenue streams. A notable product in this regard is the SpydrBlade, a miniaturized tool with dual cutting and coagulation capabilities, currently awaiting regulatory approvals. Creo's innovations also address the need for specialized training for surgeons and endoscopists, underscoring the importance of their products in delicate procedures like removing oesophageal cancer. The company's approach involves establishing centers of excellence to concentrate expertise and training, a strategy likely to boost sales and market presence in the UK, US, and Asia Pacific. Financially, Creo is well-positioned, having raised significant capital in March 2023 and expecting to be EBITDA positive by 2025. This financial stability supports their ambitious sales, marketing, and product development plans. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 27, 2023 06:55 AM Eastern Standard Time

Video

Cellular Goods highlights recent developments and milestones for its 'Look Better' skincare range

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor takes Proactive's Stephen Gunnion through the latest developments in the company's wellness business. Taylor highlighted the recent launch of their wellness division in several European countries, including France, Germany, Austria, Italy, Portugal, and Spain. This expansion aligns with their strategy to enter cannabigerol (CBG) friendly markets with high consumer demand and promising return on investment. The company's aim is to increase accessibility to its 'Look Better' skin range and enhance geographic distribution. Taylor also mentioned Cellular Goods' successful launch on the Sephora UK marketplace back in May, emphasizing the significance of the company's participation in promotional campaigns to increase product awareness. As the first CBD skincare brand in Sephora's offerings, these campaigns have been pivotal in expanding their customer base and leveraging their brand. Additionally, Taylor discussed the inclusion of their rejuvenating face serum in Jamie Greenberg's highly-anticipated 'swag bag', a significant endorsement from the renowned makeup artist. This has helped boost their presence and customer traction in the US market. Another strategic partnership highlighted is with Chill.com, a wellness product platform in the UK and the US. This collaboration aims to enhance the company's profile and sales in these regions, positioning Cellular Goods as a leading skincare brand on the platform. Looking ahead, Taylor expressed plans to continue expanding the 'Look Better' skincare range into new markets, focusing on revenue growth and increasing visibility among new and existing customers. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 27, 2023 06:53 AM Eastern Standard Time

Video

Women and Alzheimer’s Disease Subject of Giving Tuesday Webinar

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund will host Dr. Liisa Galea for a Giving Tuesday webinar on her research into women and Alzheimer’s disease. In this pre-recorded webinar, Dr. Galea presents her research on sex-based differences into the causes of Alzheimer's disease and discusses her findings with Meg Smith, CEO of Cure Alzheimer's Fund. Dr. Liisa Galea is the Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and a Professor of Psychiatry at the University of Toronto. Dr. Galea is a world-renowned expert in sex hormone influences on brain and behavior, with a focus on dementia and stress-related psychiatric disorders. Her research examines the intersection of hormones, and stress on brain plasticity in males and females. “Women develop Alzheimer's disease at twice the rate of men. Dr. Galea’s research into why women are more susceptible to Alzheimer’s and what is driving increased risk is impressive,” said CEO Smith. “She is a tireless advocate for women’s health research and for sex and gender-based analysis to improve cognitive aging for both women and men. We are lucky to hear from her.” “There is a lot of talk about precision medicine, the idea that we can tailor treatments based on our genes. But we rarely talk about how different treatments might be needed to combat neurodegenerative diseases like Alzheimer’s based on our sex,” said Galea. “The top three risk factors for late onset sporadic Alzheimer’s disease include APOE4 genotype and female sex. If you are an APOE4 carrier and a female you have an even greater risk of developing Alzheimer’s disease than if you are male carrier. Why not harness this information to see whether we can discover new therapies to combat this devastating illness. It’s time we figured out how sex plays a role, not only in the risk and progression of Alzheimer’s disease, but whether or not, different treatments may need to be tailored by sex.” For more information and to view the webinar, please visit Cure Alzheimer’s Fund at CureAlz.org and https://bit.ly/49jqQuO for the webinar. The webinar takes place during Alzheimer’s Awareness Month in November. It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease two-thirds of those who are afflicted are women. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://www.curealz.org/. To learn about our the impact of Alzheimer’s on women and women working towards a cure, visit https://womenandalzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://www.CureAlz.org

November 27, 2023 05:01 AM Eastern Standard Time

Putting the Brakes on Distracted Driving This Holiday Season

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/-m__hB55lSE The holiday season is here – and that means there will be an increase of motorists on U.S. roadways. With more families hitting the road, it’s an important time to discuss the dangers and consequences of distracted driving. The 2023 Travelers Risk Index on distracted driving found that 70% of consumers feel that distracted driving is more of a problem now than it was over the past few years. Following are additional highlights from the 2023 Travelers Risk Index: · 80% make or receive calls. · 57% use handheld devices. · 28% post on social media. · 27% take photos or videos. The Travelers Institute, the public policy division at Travelers, has been raising awareness of the dangers of distracted driving through its Every Second Matters® campaign – an initiative that began in 2017. Since the campaign started, the Travelers Institute has published a number of whitepapers and resources to help consumers understand the risks and learn how to be safe behind the wheel. The Travelers Institute was joined by Cambridge Mobile Telematics (CMT), the world’s largest telematics solution provider, which regularly publishes new distracted driving data insights and road safety reports throughout the year. According to its new report, The State of Distracted Driving in 2023 & the Future of Road Safety, CMT reports that the 23% surge in distracted driving in 2022 caused an additional 420,000 crashes, 1,000 fatalities, and $10 billion in economic damages. Additionally, a new analysis from CMT shows that distracted driving increased by 9.2% on Thanksgiving Day from 2020 to 2022. For more information, visit TRAVELERSINSTITUTE.ORG AND CMT.AI. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 22, 2023 02:00 PM Eastern Standard Time

Video

News Release

Renovaro Biosciences CEO unveils potential breakthrough therapies and AI partnerships for 2024

Renovaro Biosciences Inc

Renovaro Biosciences CEO Dr Mark Dybul joined Steve Darling from Proactive to share news about the significant progress the company is poised to make following the signing of a definitive agreement to merge with GEDiCube, a UK-based medical AI company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. GEDiCube is set to rebrand as Renovaro.AI, and together, the entities are looking to hasten diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases. Dybul highlighted to Proactive that while Renovaro is currently concentrated on pancreatic cancer research, plans are afoot to extend their focus to include other solid tumors that are typically associated with a short life expectancy. These will be part of the first human Phase I/IIa studies anticipated to commence by mid-2024. He noted the potential of GEDi Cube’s AI technology to refine the focus of upcoming human trials on those cancers that are most amenable to treatment. Furthermore, the technology is expected to enrich the database of crucial markers for early diagnosis and tracking disease progression, thereby fostering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of completely new therapeutic options. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 22, 2023 10:44 AM Eastern Standard Time

Video

1 ... 50 51 52 53 54 ... 283